To facilitate rational, data-driven decisions about vaccine candidate advancement, we compared Bacillus Calmette-Guérin (BCG) [8] and six novel TB vaccine candidates, including MVA85A [9, 10], AERAS-402 [11], H1:IC31 [12], M72/AS01E [13, 14], ID93+GLA-SE [15] and H56:IC31 [16], by their induced antigen-specific CD4 and CD8 T cell responses from data generated in human clinical trials previously completed at the South African TB Vaccine Initiative. This evidence concerns the gene CD8A and tuberculosis.